United States (National)
Not enough data
Diana Isaacs covers a range of topics related to diabetes, healthcare, and pharmaceuticals. Her articles heavily rely on cited data and announcements, indicating that she is likely to be interested in pitches backed by credible research findings or significant industry developments.
Given the technical nature of her coverage, Diana would benefit from outreach from experts who can provide detailed insights into new diabetes treatments, medical technologies, and updates in standards of care for diabetic patients. Sources with access to cutting-edge research or those involved in developing new pharmaceuticals may find success reaching out to her.
While no specific geographic focus is mentioned for Diana's coverage area, it seems global due to the nature of medical advancements being discussed without any regional limitations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Diana Isaacs
In this podcast, Diana Isaacs, PharmD, CDCES, talks about continuous glucose monitoring (CGM) technology and how it can be used for medicine adjustments and lifestyle interventions for patients with diabetes. Dr Isaacs discusses how this technology has evolved over time, how clinicians can strategically use CGM technology in their practice, and more.
In this podcast, Diana Isaacs, PharmD, CDCES, talks about smart insulin pens and pen caps and how they can help patients with diabetes manage their insulin. Dr Isaacs discusses the benefits of using this technology, important education points for clinicians when implementing their use in care, and more.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.
The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.
By: Diana Isaacs, Natalie Bellini
This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts discuss the implications of Dexcom announcing availability of their Stelo sensor and the FDA clearance of the Omnipod 5 for type 2 diabetes.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.
By: Diana Isaacs, Natalie Bellini
A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.
By: Natalie Bellini, Diana Isaacs
Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.
(833) 317-6278 